Terug
28
Ook genoteerd als
UCBJF
OTC
Dagbereik
€ 143,81
€ 145,91
52-Weeksbereik
€ 71,16
€ 168,76
Volume
3.348
50D / 200D Gem.
€ 152,79
/
€ 129,82
Vorige Slotkoers
€ 141,62
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (626 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 36,8 | 0,4 |
| P/B | 5,1 | 2,9 |
| ROE % | 14,3 | 3,7 |
| Net Margin % | 20,1 | 3,9 |
| Rev Growth 5Y % | 6,5 | 10,0 |
| D/E | 0,2 | 0,2 |
Koersdoel Analisten
Geen analistendekking beschikbaar
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2030 |
€ 11,65
€ 11,29 – € 11,93
|
13 B | 1 |
| FY2029 |
€ 10,16
€ 9,85 – € 10,40
|
12 B | 1 |
| FY2028 |
€ 8,57
€ 8,31 – € 8,77
|
11 B | 1 |
Belangrijkste Punten
Revenue grew 6,51% annually over 5 years — modest growth
Earnings grew 40,52% over the past year
ROE of 14,33% — decent returns on equity
Net margin of 20,13% shows strong profitability
Debt/Equity of 0,21 — conservative balance sheet
Generating 1,81B in free cash flow
Groei
Revenue Growth (5Y)
6,51%
Revenue (1Y)20,86%
Earnings (1Y)40,52%
FCF Growth (3Y)101,55%
Kwaliteit
Return on Equity
14,33%
ROIC6,41%
Net Margin20,13%
Op. Margin15,06%
Veiligheid
Debt / Equity
0,21
Current Ratio1,38
Interest Coverage9,11
Waardering
P/E Ratio
36,79
P/B Ratio5,07
EV/EBITDA49,16
Dividend Yield0,01%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 20,86% | Revenue Growth (3Y) | 18,99% |
| Earnings Growth (1Y) | 40,52% | Earnings Growth (3Y) | 108,88% |
| Revenue Growth (5Y) | 6,51% | Earnings Growth (5Y) | 9,06% |
| Profitability | |||
| Revenue (TTM) | 7,44B | Net Income (TTM) | 1,50B |
| ROE | 14,33% | ROA | 8,25% |
| Gross Margin | 71,14% | Operating Margin | 15,06% |
| Net Margin | 20,13% | Free Cash Flow (TTM) | 1,81B |
| ROIC | 6,41% | FCF Growth (3Y) | 101,55% |
| Safety | |||
| Debt / Equity | 0,21 | Current Ratio | 1,38 |
| Interest Coverage | 9,11 | Dividend Yield | 0,01% |
| Valuation | |||
| P/E Ratio | 36,79 | P/B Ratio | 5,07 |
| P/S Ratio | 7,41 | PEG Ratio | 0,76 |
| EV/EBITDA | 49,16 | Dividend Yield | 0,01% |
| Market Cap | 55,06B | Enterprise Value | 55,06B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 7,44B | 6,15B | 5,25B | 5,52B | 5,78B |
| Net Income | 1,50B | 1,07B | 343,00M | 418,00M | 1,06B |
| EPS (Diluted) | 3,86 | 2,74 | 0,88 | 1,08 | 2,73 |
| Gross Profit | 5,29B | 4,40B | 3,55B | 3,84B | 4,34B |
| Operating Income | 1,12B | 1,32B | 604,00M | 585,00M | 1,28B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 18,15B | 17,35B | 15,54B | 15,87B | 14,21B |
| Total Liabilities | 7,29B | 7,32B | 6,56B | 6,80B | 5,82B |
| Shareholders' Equity | 10,86B | 10,03B | 8,98B | 9,06B | 8,39B |
| Total Debt | 2,24B | 3,03B | 3,04B | 2,90B | 2,12B |
| Cash & Equivalents | 2,25B | 1,57B | 861,00M | 899,00M | 1,26B |
| Current Assets | 6,05B | 4,79B | 3,44B | 3,30B | 3,71B |
| Current Liabilities | 4,40B | 3,53B | 2,62B | 3,11B | 2,82B |
Strategiescores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
Custom
Cash Flow Compounder
#851 of 1024
Recente Activiteit
Ingestapt
Cash Flow Compounder
Mar 24, 2026